STAT

Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows

A type of targeted chemotherapy developed by China-based Kelun-Biotech and licensed to Merck cut the risk of tumor ...
STAT

Sanofi advances a drug for a rare, platelet-destroying disease

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
STAT

ASCO day 2: A tragic paradox, Gilead updates, and lots of Pfizer news

Matthew Herper covers medical innovation — both its promise and its perils. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...
STAT

Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study

Biogen is moving its tau-targeting Alzheimer's drug into Phase 3 studies, despite mixed data from a Phase 2 trial.
STAT

Avidity, FDA reach agreement on accelerated filing of rare disease drug

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
STAT

Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission

Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a ...
STAT

FDA to reconsider treatment for rare cancer after its surprise rejection

The companies developing Ebvallo reached an agreement with the FDA to address its main reason for rejecting the drug.
STAT

‘No drama’ Diamantas should serve biotech well as acting FDA chief

Kyle Diamantas, the acting commissioner of the FDA, is expected to be a drama-free, stabilizing caretaker at the top of the ...
STAT

FDA approves schizophrenia drug that could alter how disorder is treated

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
STAT

Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
STAT

Vinay Prasad is outraged, and now at the FDA. How will biotech deal?

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...
STAT

New stakes in the vaccine dispute and a boost for biotech

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.